Thioridazine is indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. Due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs.

Trifluoperazine HCl is indicated for the management of schizophrenia. Trifluoperazine HCl is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine HCl is not the first drug to be used in therapy for most patients with non-psychotic anxiety.

Zyprexa^® (olanzapine) is an atypical antipsychotic indicated for the treatment of schizophrenia and bipolar disorder and — in combination with fluoxetine — for the treatment of treatment resistant depression.